226950.KQ
OliX Pharmaceuticals,Inc
KOE · Healthcare · Biotechnology · KR
KRW 91,800.00
−8.38%Year over year
Reported trailing growth
- Revenue
- +80.9%
- EBITDA
- —
- EBIT
- -37.3%
- EPS
- +76.1%
- Free cash flow
- +0.3%
- Operating cash flow
- -34.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +16.3%
- EBITDA
- +2.7%
- EBIT
- +3.1%
- Net income
- +60.1%
- EPS
- +66.5%
- Free cash flow
- +59.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026